Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes.

X
Trial Profile

Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary) ; Glibenclamide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 03 Mar 2010 Results of the initial 24-week treatment period published in Current Medical Research and Opinion.
    • 18 Oct 2009 Results presented at the 20th World Diabetes Congress.
    • 01 Oct 2009 Results have been presented at the 45th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top